Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of adjunctive seltorexant in major depressive disorder with insomnia symptoms
2020-000338-16Phase 3Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Aug 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in major depressive disorder (MDD) comparing Seltorexant 20 mg adjunctive arm with Placebo adjunctive arm (2 arms). Primary endpoint: Primary efficacy endpoint. Started Aug 2020; status: completed.
02
Drugs
seltorexant
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on 2020-000338-16.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-000338-16.